• Vaccine Name: rBCG-SIVgag
• Target Pathogen: Simian Immunodeficiency Virus
• Target Disease: Simian AIDS
• Vaccine Ontology ID: VO_0004789
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Macaque
• Antigen: M. bovis BCG-SIV Gag followed by boosting with rDIsSIVgag (Ami et al., 2005).
• gag gene engineering:
  • Type: Recombinant vector construction
  • Description: The SIV gag gene was used in generation of a recombinant vector vaccine (Ami et al., 2005).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001023
• Immunization Route: Intradermal injection (i.d.)

Macaque Response

• Host Strain: Macaca fascicularis
• Host gender: Male
• Vaccination Protocol: The macaques were divided into 5 groups. Group 1 (control group) received rBCG-PSO246 followed by two inoculations of rDIsLacZ. Group 2 (rBCG group) received rBCG-SIVgag followed by two inoculations of rDIsLacZ. Group 3 (rBCG/rDIs group) received rBCG-SIVgag followed by two inoculations of rDIsSIVgag. Group 4 (rDIS group) received two inoculations of rDIsSIVgag followed by rBCG-pSO246. Group 5 (rDIs/rBCG group) received two inoculations of rDIsSIVgag followed by rBCG-SIVgag (Ami et al., 2005).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: All groups were mucosally challenged with two thousand 50% tissue culture infectious doses of SHIV KS661c at 64 weeks after immunization, these were intrarectally administered (Ami et al., 2005).
• Efficacy: Only the macaques in group 3 (rBCG/rDIs) showed evidence of protective immune responses, the macaques in this group remained clinically healthy for a one year observation period. During this same observation period, by day 170, 6 macaques in the other 4 groups had died with symptoms consistent with simian AIDS. The rBCG/rDIs group vaccinated with the priming-boosting regimen had a superior survival rate than the other groups receiving vaccine protocols and the control group (Ami et al., 2005).